Tetradecylthioacetic Acid for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / ChatGPT 6

Also known as: TTA, Tetradecyl Thioacetic Acid, 2-(tetradecylthio)acetic acid, 2-tetradecylsulfanylacetic acid, 1-(carboxymethylthio)tetradecane

Motivation

Tetradecylthioacetic acid is a laboratory-made fatty acid designed to behave differently from the fats found in food. Its structure allows it to influence how cells handle and use fat. That makes it a subject of interest for adults exploring the relationship between blood fats, body composition, and long-term health, including those who already maintain demanding nutrition and exercise routines.

The compound originated in metabolic research and later entered small human studies involving diabetes, inflammatory skin disease, and treatment-related changes in blood fats. It has also attracted attention as a supplement. These different settings raise questions about how laboratory experiments, short clinical exposures, and commercial use relate to one another, especially when the aim is preserving health over decades rather than changing a blood test over weeks.

This review examines the evidence for benefits and harms, the relevance of the studied populations, and the practical meaning of dose, product quality, interactions, and monitoring. Its focus is whether the available findings address health and longevity outcomes, and which claims rest on human observations or on biological reasoning.

Benefits - Risks - Protocol - Conclusion

These sources introduce tetradecylthioacetic acid (TTA), its biological rationale, human testing, and the distinction between blood-marker changes and health outcomes.

The evidence is concentrated in the Bergen research network. HIV (human immunodeficiency virus, which impairs immune defenses) appears in one selected study. Antiretroviral therapy (medicines that suppress HIV replication) is its background treatment. Rolf K. Berge and Kjetil Berge disclosed share ownership in Thia Medica AS in an original research disclosure. This creates a potential commercial conflict alongside limited independent human replication; it does not negate the reported findings.

Only three overview-oriented selections are included; further papers serve specific analyses below. No qualifying intervention-specific item was identified from the six prioritized platforms. Life Extension’s inaccessible search results leave its coverage uncertain; unrelated longevity articles were excluded.

Grokipedia

Tetradecylthioacetic acid

An encyclopedic overview of chemistry, proposed mechanisms, and experimental research. It is useful for orientation; its interpretations are checked against primary studies in this review.

Examine

Tetradecyl Thioacetic Acid

The accessible summary and dosage discussion introduce supplement use and human evidence. Detailed tables are partly restricted; its broad fat-loss and heart-protection language goes beyond demonstrated human outcomes.

ConsumerLab

No dedicated ConsumerLab article for tetradecylthioacetic acid was found as of September 27, 2026.

Systematic Reviews

No systematic reviews or meta-analyses for Tetradecylthioacetic Acid were found on PubMed as of September 29, 2026.

Mechanism of Action

Tetradecylthioacetic acid (TTA) is a synthetic fatty acid containing sulfur near its acid end. This blocks normal beta-oxidation (stepwise breakdown of fats for energy), while the compound promotes breakdown of other fatty acids. It activates PPARs (peroxisome proliferator-activated receptors, proteins that switch metabolic genes on or off), with activity across alpha, delta, and gamma subtypes. Human cell experiments show predominant alpha/delta activity at lower concentrations, rather than a highly selective target. Løvås et al.

  • Metabolic effects: Increased fat transport and oxidation in mitochondria (cellular energy-producing structures) can lower circulating fats. Anti-inflammatory actions also occur independently of PPAR-alpha, so receptor activation is not a complete explanation. Dyrøy et al.
  • Distribution and metabolism: Rat studies show accumulation of TTA and its delta-9 desaturase product (formed by an enzyme that inserts a double bond) in liver, heart, and fat tissue. Gudbrandsen et al. Slow metabolism involves omega-oxidation (breakdown beginning at the opposite end), sulfur oxidation, subsequent partial oxidation, and incorporation into phospholipids (membrane fats). Lundemo et al. Human enzyme-specific clearance and drug-metabolizing enzyme interactions remain insufficiently characterized.
  • Time course: Examine’s research breakdown reports a human elimination half-life (time for blood concentration to fall by half) of 8.9–14 hours, attributing it to Pettersen et al.. The primary abstract omits this estimate, preventing independent confirmation. Median (middle-ranked) blood-peak times were 2.5–4.5 hours; tissue persistence is a separate consideration.

Increased fat oxidation is therefore a biological effect, not proof of better physical function or longer life.

Historical Context & Evolution

TTA emerged from research into sulfur-modified fatty acids as tools for altering fat metabolism. Early animal experiments investigated whether resisting ordinary breakdown could prolong metabolic signaling. The intended applications centered on abnormal blood fats, excess body fat, and impaired blood-sugar control, rather than measured lifespan extension. The 2002 narrative review by Berge and colleagues summarized enhanced fatty-acid use, reduced fat accumulation, and anti-inflammatory and cancer-cell effects, predominantly from laboratory work.

Clinical exploration then tested people with treatment-associated high blood fats, type 2 diabetes, and psoriasis. The HIV pilot combined dietary changes with TTA; the diabetes study reported improved blood lipids without improved glucose metabolism. The placebo-controlled psoriasis study extended the lipid and inflammation-marker findings.

These observations encouraged interest in metabolic optimization and supplement marketing. However, animal heart experiments showed that increased fat oxidation could impair energy efficiency. Later diabetic-mouse experiments produced different cardiac responses, suggesting disease context matters. The research trajectory consequently supports biological activity with unresolved trade-offs, rather than a progression to established preventive treatment. Recent publications remain mainly preclinical, and small early trials still anchor human claims.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: human efficacy rests on one small placebo-controlled lipid trial and short uncontrolled studies, without replicated controlled clinical outcomes.

Medium 🟩 🟩

Improved blood-lipid profile ⚠️ Conflicted

A placebo-controlled psoriasis pilot reported lower total cholesterol, triglycerides (circulating fats), and non-HDL cholesterol (cholesterol outside high-density lipoprotein, or HDL, particles that transport cholesterol toward the liver). Uncontrolled diabetes and HIV studies agree, but the seven-day healthy-volunteer study found no lipid change. LDL (low-density lipoprotein, a cholesterol-carrying particle associated with artery disease) reduction is an intermediate outcome; cardiac-event prevention is untested. Net reading: lipid lowering appears in people with abnormal baseline lipids, not in healthy volunteers.

Magnitude: In 16 men with diabetes, LDL fell from 4.2 to 3.7 mmol/L after 1,000 mg/day for 28 days, an absolute fall of 0.5 mmol/L. This is an uncontrolled within-person change, not the placebo-adjusted effect of the psoriasis trial; its abstract provides no numerical lipid effect.

Low 🟩

Improved psoriatic skin lesions

A topical pilot in eight people found no advantage of 0.5% TTA over the preparation without TTA, while the oral placebo-controlled pilot measured inflammatory markers, not skin scores. Skin benefit therefore remains unestablished.

Magnitude: No significant difference in PASI (psoriasis area and severity index, a skin-lesion score) between topical TTA and the preparation without TTA at any assessment over 30 days; no oral skin-score figure was reported.

Speculative 🟨

Lower blood pressure

Rat experiments reduced blood pressure in kidney-driven hypertension (persistently high blood pressure). No human pressure reduction could be verified from the retrieved clinical abstracts or Examine summary; this remains an animal-supported hypothesis.

Reduced inflammation and oxidative damage

Small human studies report shifts in inflammatory proteins, with supporting cell and animal experiments. These unvalidated markers do not establish fewer inflammatory illnesses or better function. Human pilot, mechanistic study.

Reduced body fat

Rodent studies show less fat accumulation through increased fatty-acid use. No convincing human fat-loss outcome was identified; biochemical fat oxidation cannot substitute for measured changes in body composition.

Better glucose control

Rodent experiments suggest improved insulin action. The human diabetes study found no glucose-metabolism improvement, leaving this proposed benefit unestablished in people.

Cardiovascular protection ⚠️ Conflicted

Diabetic mice and artery-plaque models show benefits, but nondiabetic hearts lose efficiency. Different disease models plausibly explain divergent responses. Human cardiovascular protection remains unproven.

Reduced liver-fat accumulation ⚠️ Conflicted

TTA limited liver-fat accumulation in a drug-induced mouse model, whereas high-fat-fed mice accumulated more liver triglycerides. Diet and metabolic context differ. No human liver benefit is established.

Cancer prevention or control

Colon-cancer cells showed inhibited growth and cellular stress. No human cancer-prevention or treatment outcome was identified; killing cultured cells does not establish an effective or safe preventive exposure.

Preservation of bone

A rat experiment reported higher bone mineral measures and partial preservation after removal of the ovaries. No human fracture or bone-density benefit has been established.

Longer healthy lifespan

The rationale is indirect, based on metabolic and inflammatory changes. No human survival, disability-free survival, or healthy-aging outcome study was identified; disease-model benefits cannot establish general lifespan extension.

Benefit-Modifying Factors

  • Baseline lipids: The clearest signals concern abnormal blood fats. Applicability to already optimized lipid levels is uncertain; the seven-day healthy-volunteer study did not establish a lipid change. Study
  • Health conditions: Diabetes, psoriasis, and HIV-treatment-associated lipid abnormalities dominate human studies. Their inflammatory and metabolic settings differ from those of healthy adults; benefit cannot be assumed to scale with preventive effort.
  • Sex: The diabetes trial included only men. Reliable male–female comparisons of lipid response or body-fat effects are unavailable.
  • Age: The registered diabetes study enrolled ages 30–60. Response in adults over 65, including those with low muscle mass or frailty, is unknown. Trial
  • Genetics: No validated human genetic predictor of TTA response was identified. Receptor experiments do not establish a usable genetic test or genotype-based dose.
  • Diet and duration: Dietary intervention confounded the HIV pilot. Differences between seven-day healthy-volunteer testing and four-week disease studies could reflect duration, starting lipids, diet, or all three rather than a true contradiction. HIV study

Potential Risks & Side Effects

Long-term cancer, reproductive, developmental, kidney, and cardiac safety have not been adequately characterized in humans. Consumer reports of cramps or fluid retention lack verified incidence and causality; electrolyte depletion is not established by the short human trials. Absence of a detected serious event in small studies cannot exclude rare or delayed harm.

High 🟥 🟥 🟥

No risk reaches High: replicated controlled human adverse-event or organ-harm data are absent.

Medium 🟥 🟥

No risk reaches Medium: the accessible human safety evidence is brief, small, and largely uncontrolled rather than a controlled demonstration of a specific adverse outcome.

Low 🟥

Mild adverse events during short-term exposure

The seven-day study reported a few mild adverse events among 18 healthy volunteers receiving 200–1,000 mg/day. Its abstract does not identify event types or attributable incidence. Routine blood and urine tests showed no clinically important changes, which does not establish long-term safety.

Magnitude: Not quantified in available studies. The accessible primary report describes few mild events without an event count or placebo-attributable rate.

Speculative 🟨

Impaired cardiac energy efficiency ⚠️ Conflicted

Nondiabetic mouse hearts used more oxygen and recovered poorly after restricted blood flow; diabetic hearts responded differently. Disease context may determine direction. Human cardiac harm remains unresolved.

Liver-fat accumulation and metabolic remodeling ⚠️ Conflicted

High-fat-fed mice accumulated liver triglycerides despite lower blood triglycerides; another mouse model showed protection. These are model-dependent responses. Human liver injury risk is unquantified.

Altered essential-fat balance

Human diabetes data showed lower circulating long-chain omega-3 fats (a family of dietary fats), including docosahexaenoic acid. Harmful deficiency was not demonstrated; animal tissue responses differ, so blood changes cannot establish whole-body depletion.

Adverse vascular response to local delivery ⚠️ Conflicted

TTA-coated stents in pigs worsened arterial-wall thickening; balloon delivery in pigs reduced narrowing. Delivery method and tissue exposure differed. These conflicting animal findings do not establish oral human harm.

Long-term rat exposure changed circulating vitamin-related metabolites. These findings do not prove human nutrient deficiency, but complicate assumptions that sustained metabolic stimulation is nutritionally neutral.

Risk-Modifying Factors

  • Baseline biomarkers: Existing liver-test abnormalities, impaired kidney function, or low omega-3 status complicate interpretation of subsequent changes. No TTA-specific laboratory threshold predicting harm is validated.
  • Heart disease: Impaired cardiac reserve could matter given animal oxygen-efficiency findings. Human safety in heart failure or recent myocardial infarction (heart muscle injury) is undetermined; favorable disease-model experiments do not define a safe subgroup.
  • Sex and reproduction: Sex-specific adverse-event rates are unavailable. Pregnancy, breastfeeding, and fertility outcomes have not been established.
  • Age: Older adults with multiple conditions or medications were not adequately represented. There is no validated geriatric dose adjustment or estimate of age-related accumulation.
  • Genetics: No clinically validated genetic predictor of toxicity or clearance was identified. Experiments in animals lacking selected receptor genes do not establish human testing criteria.
  • Exposure: Most human oral evidence covers seven to 28 days. Higher doses, repeated courses, and months or years of use extend beyond the tested safety window.

Key Interactions & Contraindications

Human interaction studies are insufficient. The following are mechanistic cautions or evidence gaps, not established label contraindications; no validated timing separation eliminates them.

  • Lipid-lowering medicines — caution: Statins (atorvastatin, rosuvastatin; medicines reducing cholesterol production) and fibrates (fenofibrate, gemfibrozil; medicines that lower blood fats) could overlap with TTA’s effects. Combined muscle/liver safety is unknown; the diabetes trial excluded lipid-lowering drugs. Concurrent exposure requires separate interpretation. Trial
  • Diabetes medicines — monitor: Insulin and sulfonylureas (gliclazide, glimepiride; medicines increasing insulin release) create a theoretical low-glucose concern if metabolic effects combine. TTA did not improve glucose in its human diabetes study, so this interaction is unproven. Glucose measurements distinguish symptoms from assumptions.
  • Blood-pressure medicines (amlodipine, losartan) — monitor: Such medicines could theoretically combine with proposed pressure effects and cause dizziness or low pressure. Human interaction magnitude is unknown; repeated seated and standing measurements would clarify an observed symptom.
  • Antiretrovirals — caution: Protease inhibitors (ritonavir, lopinavir; medicines blocking viral protein processing) were represented in the HIV pilot. Ten participants cannot exclude altered drug exposure or long-term toxicity; that study is not a formal interaction assessment. Pilot
  • Antipsychotics (olanzapine, clozapine; medicines treating psychosis, or impaired reality perception) — caution: Combining them with TTA increased weight gain in female rats. Human relevance is unknown; assuming that TTA prevents medication-associated weight gain could obscure the opposite response. Animal study
  • Anticoagulants (warfarin, apixaban; medicines reducing blood clotting) and nonprescription medicines — caution: These medicines, aspirin, ibuprofen, and paracetamol lack characterized TTA interaction data. Excess bleeding or organ toxicity is not demonstrated; safe coadministration and dose adjustments cannot be inferred from the absence of reports.
  • Fish oil — caution: A 50-week rat study found additive cholesterol lowering with TTA and altered oxidative-damage markers. Human benefit and safety of combined use remain untested; no validated dose adjustment or compensatory fish-oil dose exists.
  • Other lipid supplements — caution: Niacin and red yeast rice may add to lipid effects. Combined liver and muscle safety remain untested; no validated dose adjustment or timing separation is established.
  • Weight-loss combinations — caution: Oleoylethanolamide (a lipid signal that suppresses appetite) is marketed alongside TTA. Controlled human combination data are absent; adding stimulants or fasting introduces separate appetite, pressure, and hydration effects that impede attribution.

Populations who should avoid Tetradecylthioacetic Acid:

  • Pregnancy, breastfeeding, and children under 18: avoidance is precautionary because developmental safety is unstudied.
  • Known allergy to TTA or formulation ingredients: further exposure presents a potential allergic-reaction risk.
  • Significant active heart, liver, or kidney disease outside a monitored research setting: safety and dose adjustment are undefined; no validated TTA-specific severity cutoff exists.

These are evidence-gap exclusions, not an approved prescribing label. The diabetes study excluded significant other disease and blood pressure recorded as 170/110 mmHg; its eligibility rules do not establish a universally safe range below that value.

Risk Mitigation Strategies

  • Bounded exposure: Research protocols limited oral dosing to seven or 28 days. Keeping those limits explicit prevents short-term tolerability from being mistaken for evidence of safe indefinite use; a safe chronic dose is unknown.
  • Cardiac symptom capture: New chest discomfort, breathlessness, fainting, or reduced exercise tolerance are the symptoms that would reflect the unresolved cardiac concern in a monitored exposure; recording them addresses that concern rather than assuming a benign metabolic adjustment.
  • Laboratory comparison: Baseline, day-14, and day-28 lipid, liver, and kidney comparisons can detect changes missed by subjective well-being. This is an extrapolated surveillance approach, not a proven method of preventing delayed toxicity.
  • Nutrient interpretation: Diet records and consistent fatty-acid measurements help distinguish altered circulating omega-3 levels from deficiency. Empirical high-dose potassium or vitamin replacement is not an established mitigation for TTA-related symptoms.
  • Product and co-exposure records: Documented batch identity, actual dose, and stable accompanying medicines reduce contamination and attribution errors. No amount of product testing removes uncertainty about the compound’s own long-term effects.

Therapeutic Protocol

  • Status: No established practitioner consensus or validated longevity regimen was identified. Published hospital research and Examine’s supplement-oriented schedule are descriptive alternatives; neither establishes a preventive indication.
  • Research doses: Pettersen and colleagues studied 200, 600, or 1,000 mg orally once daily for seven days in healthy volunteers. These were parallel dose groups, not a demonstrated individual escalation schedule. Study
  • Four-week regimen: The Bergen diabetes protocol used 1,000 mg in capsules once daily for 28 days. Lipids, glucose, and safety blood parameters were measured at baseline, day 14, and day 28. Protocol
  • Alternative schedule: Examine describes 1 g/day split with meals. No head-to-head trial establishes an advantage over once-daily dosing; it is not attributed to a verified leading-practitioner protocol.
  • Time of day and half-life: Examine’s research breakdown reports 8.9–14 hours, attributed to the phase-1 study but unconfirmed from its full text. No morning/evening advantage or clearance-based dosing interval is validated.
  • Baseline and disease context: Raised blood lipids characterized the efficacy studies. Diabetes did not reliably confer a glucose response; existing cardiac, liver, or kidney disease has no validated adjustment algorithm.
  • Sex, age, and genetics: No evidence-based sex- or genotype-specific dosing exists. The male diabetes cohort was aged 30–60; older adults and women lack adequate comparative dosing data.
  • Other formulations: Topical 0.5% TTA twice daily for 30 days did not outperform the preparation without TTA for psoriasis in a small pilot. Topical and oral exposures are not interchangeable longevity protocols. Study

Discontinuation & Cycling

  • Duration: Human research used short courses, not lifelong treatment. Persistence of lipid effects after cessation and safety of extended exposure are poorly characterized.
  • Withdrawal: No characteristic dependence or withdrawal syndrome is established. Return of biomarkers toward baseline is possible but has not been quantified sufficiently to predict timing.
  • Tapering: No evidence-based taper is described. The finite research courses do not establish a need for tapering; uncertain tissue persistence prevents assigning a validated washout interval.
  • Cycling: No controlled evidence shows that intermittent cycles preserve efficacy or reduce toxicity. Rest periods cannot be assumed to eliminate accumulated exposure.

Sourcing and Quality

  • Identity: TTA is a specific synthetic sulfur-containing fatty acid, not interchangeable with fish oil or thioctic acid. Ingredient identity is documented in the US Food and Drug Administration (FDA, the US medicines and food regulator) substance record; that registry is not an approval.
  • Purity: Meaningful documentation includes independent batch-specific identity and potency testing, plus contaminant, residual-solvent, and microbial results. A supplier’s purity percentage alone does not establish suitability for human administration.
  • Formulation: The studies used defined oral material. Mixed weight-loss formulas and added electrolytes introduce separate exposures; their labels cannot establish equivalence to trial capsules.
  • Brand verification: No retail brand or compounding pharmacy was verified as matching trial material with independently confirmed human-use quality. Brand endorsement would exceed the available evidence; research-use chemical suppliers are not clinical-product validation.

Practical Considerations

  • Time to effect: Human lipid signals were observed over four weeks; seven-day healthy-volunteer testing did not establish lipid changes. A change in energy or sweating is not a validated indicator of response.
  • Common pitfalls: Fat oxidation, fat loss, and longer life are different outcomes. Lower blood fats can coexist with unfavorable tissue changes in animals; isolated lipid success does not measure total benefit.
  • Regulatory status: No approved longevity indication was identified. The FDA explicitly states that substance registration does not imply regulatory review or approval. Local product legality and quality remain separate questions.
  • Access and cost: Availability through supplement or chemical channels does not establish clinical-grade access. There is no verified standardized treatment price; independent testing and monitoring may exceed the material cost.
  • Evidence access: Several foundational trials were assessable only through their abstracts and registry records. Unreported numerical effects, adverse-event types, or clearance parameters were not reconstructed from commercial claims.

Interaction with Foundational Habits

  • Sleep: Direction: none established; direct effects on sleep quality or sleep architecture are unstudied. Neither sedative nor stimulant benefits are established; recording sleep alongside dosing can identify individual changes without assigning causality prematurely.
  • Nutrition: Direct interaction is plausible through altered fatty-acid processing. Stable diet helps interpret lipid changes; the HIV study included a cholesterol-lowering diet. No human evidence shows that extra dietary fat, omega-3 supplements, or a particular meal schedule improves the net result.
  • Exercise: Direction: none demonstrated in humans; potentiating or blunting effects on training adaptation are unestablished. Increased animal fat oxidation does not demonstrate improved endurance; reduced cardiac efficiency in some models makes exercise tolerance a relevant observation rather than an expected benefit.
  • Stress management: No direct interaction with relaxation practices or psychological stress regulation is established. Maintaining a consistent routine limits changes in sleep, appetite, and perceived energy that could otherwise be incorrectly attributed to TTA.

Monitoring Protocol & Defining Success

Before a research exposure, baseline assessment would document fasting lipids, glucose, liver and kidney tests, blood count, electrolytes, blood pressure, weight, symptoms, medicines, and supplements. This records intended outcomes and pre-existing abnormalities. No TTA-specific functional target ranges are validated; individual goals and changes from baseline provide context.

Ongoing measurements at day 14 and day 28 mirror the registered diabetes study. Assessment two to four weeks after cessation is an extrapolation to document recovery; symptoms warrant earlier assessment. Success means reproducible lipid improvement without worsening symptoms, organ tests, or physical capacity. These short-term observations remain descriptive and cannot establish long-term safety or lifespan benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting lipid profile LDL below 100 mg/dL (2.6 mmol/L), triglycerides below 100 mg/dL (1.1 mmol/L), HDL above 50 mg/dL (1.3 mmol/L); no TTA-specific target, so track change from baseline Measure intended response Include LDL, HDL, non-HDL cholesterol and triglycerides; use consistent fasting conditions and laboratory. Conventional intervals are looser (triglycerides below 150 mg/dL, 1.7 mmol/L; LDL below 130 mg/dL, 3.4 mmol/L) and are not an individualized prevention goal.
Fasting glucose 75–90 mg/dL (4.2–5.0 mmol/L); no TTA-specific target, so track baseline and low-glucose symptoms Detect metabolic change Morning sampling after a consistent fast; diabetes medicines strongly affect interpretation. Conventional interval: 70–99 mg/dL (3.9–5.5 mmol/L).
Liver enzymes and bilirubin ALT and AST about 10–25 U/L, bilirubin 0.3–1.0 mg/dL (5–17 µmol/L); no TTA-specific optimum, so track baseline Detect possible liver injury Alanine and aspartate aminotransferases (enzymes that process amino acids, the building blocks of proteins) are liver-injury markers; bilirubin reflects bile-pigment handling. Conventional upper limits are about 35–45 U/L (ALT, AST) and 1.2 mg/dL (bilirubin). Rising results indicate possible liver injury rather than a dose-optimization target.
Creatinine and estimated filtration rate Estimated filtration rate above 90 mL/min/1.73 m²; creatinine about 0.7–1.1 mg/dL, varying with muscle mass; no TTA-specific target, so track baseline Detect kidney change Creatinine is a muscle-derived waste marker; filtration estimates depend on age and muscle mass. Conventional threshold: 60 mL/min/1.73 m² or higher; creatinine 0.6–1.3 mg/dL. Normal values do not validate drug clearance.
Sodium, potassium, magnesium Sodium 138–142 mmol/L, potassium 4.0–4.8 mmol/L, serum magnesium 2.0–2.4 mg/dL (0.82–0.99 mmol/L); no TTA-specific optimum, so track baseline Evaluate cramps or weakness Conventional intervals: sodium 135–145 mmol/L, potassium 3.5–5.0 mmol/L, magnesium 1.7–2.2 mg/dL. Electrolyte replacement is not supported solely by symptom reports; excessive supplementation can itself cause harm.
Complete blood count Hemoglobin 13.5–15.5 g/dL (men) or 12.5–14.5 g/dL (women), platelets 175–250 ×10⁹/L; no TTA-specific target, so track baseline Identify blood-cell changes Measures red cells, white cells, and platelets; included as general safety surveillance in early human testing. Conventional intervals are wider (hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; platelets 150–400 ×10⁹/L).
Blood pressure and resting pulse Below 120/80 mmHg and resting pulse 55–70 beats per minute; no TTA-specific target, so track reproducible baseline and symptoms Detect circulation changes Use the same validated device and resting conditions; standing measurements help interpret dizziness. Conventional thresholds: 130/80 mmHg (US) or 140/90 mmHg (Europe) for hypertension; pulse 60–100 beats per minute.
Plasma fatty-acid profile, if available Omega-3 index 8–12% when measured; no TTA-specific target, so track the same assay from baseline Characterize omega-3 shifts The omega-3 index is the percentage of eicosapentaenoic and docosahexaenoic acids (two marine omega-3 fats) among red-blood-cell fatty acids. Plasma change is not equivalent to tissue deficiency; no validated supplementation trigger exists. Conventional view: an index below 4% is considered low.

Qualitative tracking accompanies laboratory data:

  • Physical capacity: Exercise tolerance, breathlessness, muscle symptoms, and recovery.
  • General tolerance: Digestive symptoms, dizziness, swelling, and new skin reactions.
  • Daily function: Sleep, energy, and cognitive clarity; improvement alone cannot establish disease prevention.

Emerging Research

  • Human trial landscape: The September 27, 2026 registry search found no ongoing TTA study. NCT00605787, “TTA in Treatment of Diabetes and Dyslipidemia” (abnormal blood fats), is completed: phase 2, 16 men, 28-day exposure, primary outcome plasma lipids. It is the published diabetes cohort, not new confirmatory evidence.
  • Context-dependent liver effects: Bjørndal et al., 2024 studied 40 mice exposed to altered fat metabolism. Protection in this induced model supports a metabolic hypothesis, while the liver-fat increase in Lundåsen et al., 2020 shows why human imaging and organ-safety outcomes could weaken it.
  • Cardiac translation: Hafstad et al., 2009 and Khalid et al., 2011 motivate testing whether baseline metabolic disease predicts favorable or unfavorable heart responses. A lipid benefit with worse cardiac efficiency would materially change the longevity assessment.
  • Metabolic markers: Dankel et al., 2023 identified circulating changes associated with increased liver fat oxidation in rats. Such markers might document biological activity, but cannot independently establish improved function, safe exposure, or slower aging.
  • Decisive outcomes: Independent controlled studies of sustained lipid response, body composition, physical function, cardiovascular events, and long-term safety could strengthen or overturn current expectations. No registered lifespan trial or validated biological-aging outcome study was identified.

Conclusion

Tetradecylthioacetic acid is a synthetic fatty acid with clear biological activity and a limited human evidence base. Its most credible benefit is a short-term improvement in blood fats in selected clinical settings. That signal includes a small study comparing the compound with an inactive preparation, supported by studies without comparison groups in people with abnormal blood fats related to disease or medication. It does not establish weight loss, improved glucose control, fewer heart attacks, or longer life in health-focused adults.

Short human exposures were generally tolerated, but they provide little information about cumulative exposure or uncommon harms. Lower blood levels of some dietary fats and opposing effects in animal heart and liver studies complicate the assumption that increased fat use is uniformly beneficial. Whether these animal findings apply to humans remains uncertain; they do not prove that the same harms occur in people.

Most supporting research comes from a closely connected investigator network, with disclosed commercial interests involving Thia Medica. It is also unclear whether commercial products match the studied material, and interaction data and a validated long-term regimen are lacking. For adults already investing in nutrition, exercise, and careful monitoring, a measurable change in blood fats remains distinguishable from a demonstrated improvement in overall health. The current evidence supports an experimental effect on how the body processes fat; the balance of lifetime benefit and risk remains unresolved.

Top - Benefits - Risks - Protocol